Pituitary Adenylate Cyclase-Activating Polypeptide clinical trials
Also written PACAP38.
How each study uses Pituitary Adenylate Cyclase-Activating Polypeptide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Pituitary Adenylate Cyclase-Activating Polypeptide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2006 (1)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- No phase
- 8
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 8
Danish Headache Center (6) · Song Guo (1) · Glostrup University Hospital, Copenhagen (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Neurotransmitter Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Pituitary Adenylate Cyclase-Activating Polypeptide.
- Dec 2026Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38Not applicable · Danish Headache Center
Studies
Open first, then newest update. How each study uses Pituitary Adenylate Cyclase-Activating Polypeptide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38Not yet recruitingNot applicableDanish Headache CenterNCT07342296Written as Pituitary Adenylate Cyclase Activating Polypeptide-38 (PACAP-38)
- Hypersensitivity to PACAP-38 in Post-Traumatic HeadacheStatus unknownNot applicableDanish Headache CenterNCT05378061Written as Pituitary adenylate cyclase activating polypeptide-38
- The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy VolunteersCompletedNot applicableDanish Headache CenterNCT04960657Written as PACAP38
- PACAP27 Headache Properties in Migraine Without Aura PatientsCompletedNot applicableDanish Headache CenterNCT03471039Written as PACAP27
- The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine PatientsCompletedNot applicableSong GuoNCT02364453Written as PACAP38
- PACAP Induced Migraine Attacks in Patients With High and Low Genetic LoadCompletedNot applicableDanish Headache CenterNCT02158221Written as PACAP
- Effect of PACAP38/VIP on Migraineurs Measured by Magnetic ResonanceCompletedNot applicableGlostrup University Hospital, CopenhagenNCT01471990Written as Pituitary Adenylate Cyclase-Activating Polypeptide-38
- PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood FlowCompletedNot applicableDanish Headache CenterNCT00380263Written as PACAP38
Given beside what is tested · 1 — Pituitary Adenylate Cyclase-Activating Polypeptide is usual care or a partner of the new treatment
Codes
What other systems call Pituitary Adenylate Cyclase-Activating Polypeptide · ClinicalTrials.gg INT008871
- MeSH (NLM) D051219Pituitary Adenylate Cyclase-Activating PolypeptideOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D051219 | Pituitary Adenylate Cyclase-Activating Polypeptide | One source ClinicalTrials.gov |
Also registered as pituitary adenylate cyclase-activating polypeptide 27 (UNII J974J07M1G) and pituitary adenylate cyclase-activating polypeptide 38 (UNII LK78T72MLT).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.